Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
199.4 EUR | -2.04% | +5.19% | -4.23% |
02:51pm | The job report just threw a spanner in the works | |
11:38am | Mizuho Initiates Charles River Laboratories International With Neutral Rating, $235 Price Target | MT |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With a 2024 P/E ratio at 28.02 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.23% | 11.42B | - | ||
+50.44% | 59.28B | B- | ||
+41.42% | 40.94B | A | ||
-5.42% | 40.17B | B | ||
-5.16% | 28.69B | C | ||
+12.90% | 26.63B | B- | ||
-20.42% | 18.89B | B | ||
+31.20% | 12.46B | C+ | ||
+0.40% | 12.42B | B+ | ||
+26.17% | 12.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- CRL Stock
- RV6 Stock
- Ratings Charles River Laboratories International, Inc.